Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week double-blind randomized trial of fesoterodine vs tolterodine ER vs placebo in overactive bladder
2007-006451-39Phase 4Completed
- Sponsor
- Pfizer
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fesoterodine in overactive bladder (OAB) (3 arms), sponsored by Pfizer. Primary endpoint: Change in mean number of urgency urinary incontinence episodes per 24 hours. Started Dec 2007; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2007-006451-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006451-39.